Literature DB >> 22527576

A review of the role of stem cells in the development and treatment of glioma.

Richard M Heywood1, Hani J Marcus, David J Ryan, Sara G M Piccirillo, Talal M Fael Al-Mayhani, Colin Watts.   

Abstract

The neurosurgical management of patients with intrinsic glial cancers is one of the most rapidly evolving areas of practice. This has been fuelled by advances in surgical technique not only in cytoreduction but also in drug delivery. Further innovation will depend on a deeper understanding of the biology of the disease and an appreciation of the limitations of current knowledge. Here we review the controversial topic of cancer stem cells applied to glioma to provide neurosurgeons with a working overview. It is now recognised that the adult human brain contains regionally specified cell populations capable of self-renewal that may contribute to tumour growth and maintenance following accumulated mutational change. Tumour cells adapted to maintain growth demonstrate some stem-like characteristics and as such constitute a legitimate therapeutic target. Cellular reprogramming technologies raise the potential of developing stem cells as novel surgical tools to target disease and possibly ameliorate some of the consequences of treatment. Achieving these goals remains a significant challenge to neurosurgical oncologists, not least in challenging how we think about treating brain cancer. This review will briefly examine our understanding of adult stem cells within the brain, the evidence that they contribute to the development of brain tumours as tumour-initiating cells, and the potential implications for therapy. It will also look at the role stem cells may play in the future management of glioma.

Entities:  

Mesh:

Year:  2012        PMID: 22527576     DOI: 10.1007/s00701-012-1338-9

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  5 in total

1.  CD15 Expression Does Not Identify a Phenotypically or Genetically Distinct Glioblastoma Population.

Authors:  Emma Kenney-Herbert; Talal Al-Mayhani; Sara G M Piccirillo; Joanna Fowler; Inmaculada Spiteri; Philip Jones; Colin Watts
Journal:  Stem Cells Transl Med       Date:  2015-05-27       Impact factor: 6.940

Review 2.  Glioma virus therapies between bench and bedside.

Authors:  Johanna K Kaufmann; E Antonio Chiocca
Journal:  Neuro Oncol       Date:  2014-01-26       Impact factor: 12.300

3.  MicroRNA-203 As a Stemness Inhibitor of Glioblastoma Stem Cells.

Authors:  Yifan Deng; Gang Zhu; Honghai Luo; Shiguang Zhao
Journal:  Mol Cells       Date:  2016-08-03       Impact factor: 5.034

4.  NAD+ bioavailability mediates PARG inhibition-induced replication arrest, intra S-phase checkpoint and apoptosis in glioma stem cells.

Authors:  Jianfeng Li; Kate M Saville; Md Ibrahim; Xuemei Zeng; Steve McClellan; Anusha Angajala; Alison Beiser; Joel F Andrews; Mai Sun; Christopher A Koczor; Jennifer Clark; Faisal Hayat; Mikhail V Makarov; Anna Wilk; Nathan A Yates; Marie E Migaud; Robert W Sobol
Journal:  NAR Cancer       Date:  2021-11-17

5.  Topoisomerase I inhibitors, shikonin and topotecan, inhibit growth and induce apoptosis of glioma cells and glioma stem cells.

Authors:  Feng-Lei Zhang; Ping Wang; Yun-Hui Liu; Li-Bo Liu; Xiao-Bai Liu; Zhen Li; Yi-Xue Xue
Journal:  PLoS One       Date:  2013-11-26       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.